期刊文献+

10-羟基喜树碱乳酸-羟基乙酸共聚物超声微泡制备及工艺优化 被引量:4

Preparation and process optimization of HCPT-loaded PLGA microvesicles by ultrasound
原文传递
导出
摘要 目的探讨超声微泡的制备条件对粒径、包封率、表面形态等的影响,确定制备超声微泡的最佳工艺条件。方法以W/O/W型乳化溶剂挥发法制备微球,采用单因素实验和正交设计实验优化制备工艺。结果制备超声微泡的最佳条件是10-羟基喜树碱(10-hydroxy-camptothecin,HCPT)25 mg,乳酸-羟基乙酸共聚物[poly(lactic-co-glycolic acid),PLGA]1.875 g,初乳和外水相体积比为1∶15,聚乙烯醇(PVA)浓度3%;此条件所制备超声微泡呈规则球形,表面光滑,电荷以-40~0 mV为主,粒径为500~1 000 nm,包封率为79.33%,载药量为0.478 3%,体外超声成像清楚。结论优化制备条件,可制备出符合注射要求的超声微泡。 Objective To investigate the effects of different technical envelopment rate, morphology of surface and so on in order to select the HCPT(10-hydroxy-camptothecin)-loaded PLGA microvesicles. Methods conditions on the microvesicle size, best technical conditions to prepare Microvesicles were prepared by a water/oil/water emulsion and solvent evaporation method. Various factors related to the envelopment rate and micmparticle size were studied, such as the ratio of water phase and oil phase, ultrasound power, and time, stirring time and so on. Single factor experiments and orthogonal design testing was carried out to optimize the technology of microvesicles preparation. Results The best processing conditions for microvesicles preparation were as following : HCPT 25 mg, PLGA 1. 875 g, the ratio of internal and external phases 1 : 15, and the PVA concentration 3%. These preparative variables produced global, smooth and glossy microvesicles. Electric charges were probably between -40 to 0 mV, microvesicles sizes ranged from 500 to 1 000 nm, envelopment rate was 79.33%, drug loading to the microvesicles was 0. 478 3%, and ultrasonic imaging was clear in vitro. Conclusion Our optimize technical conditions can prepare injectable microvesicles by ultrasound.
作者 吴青 朱照静
出处 《第三军医大学学报》 CAS CSCD 北大核心 2009年第14期1349-1352,共4页 Journal of Third Military Medical University
关键词 10-羟基喜树碱 乳酸 羟基乙酸共聚物 超声微泡 制备 优化 camptothecin poly ( lactic-co-glycolic acid) microvesicles preparation optimization
  • 相关文献

参考文献14

  • 1童林艳,胡长林,李晋芳,王志刚,程远.两种不同开放血脑屏障方法的比较[J].第三军医大学学报,2007,29(18):1749-1751. 被引量:1
  • 2Jung L L, Zamboni W C. Cellular, pharmaeokinetie, and pharmacodynamic aspects of response to camptotheeins: can we improve it? [ J ]. Drug Ressist Updat, 2001, 4(4) : 273 -288.
  • 3张力,李苏,廖海,姜文奇,管忠震.羟基喜树碱Ⅰ期药代动力学及人体耐受性临床研究[J].癌症,2001,20(12):1391-1395. 被引量:81
  • 4李苏,姜文奇,张力,廖海,管忠震.羟基喜树碱(HCPT)不同给药方式的药理学比较[J].中国临床药理学杂志,2001,17(6):427-430. 被引量:15
  • 5Shenderova A, Burke T G, Schwendeman S P. The acidic microclimate in poly (lactide-co-glycolide) microspheres stabilizes camptothecins[J]. Pharm Res, 1999, 16(2) : 241 -248.
  • 6Chow D S, Gong L, Wolfe M D, et al. Modified laetone/carboxylate salt equilibria in vivo by liposomal delivery of 9-nitro-camptothecin[ J]. Ann N Y Acad Sci, 2000, 922:164 -174.
  • 7Tardi P, Choice E, Masin D, et al. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models [J]. Cancer Res, 2000, 60(13): 3389 -3393.
  • 8周卫,翁帼英,陈文忠,庄翌,傅晓阳,程光.紫杉醇脂质体在大鼠体内的组织分布[J].中国药学杂志,2005,40(18):1402-1404. 被引量:54
  • 9Luo H, Bimbaum Y, Fishbein M C, et al. Enhancement of thrombolysis in vivo without skin and soft tissue damage by transcutaneous ultrasound[J]. Thromb Res, 1998, 89(4): 171-177.
  • 10Takeuchi M, Ogunyankin K, Pandian N G, et al. Enhanced visualization of intravascular and left atrial appendage thrombus with the use of a thrombus-targeting ultrasonographic contrast agent (MRX408A1 ): In vivo experimental echocardiographic studies [ J]. J Am Soc Echocardiogr, 1999, 12(12): 1015- 1021.

二级参考文献89

共引文献159

同被引文献35

  • 1Feinstein S B, Shah P M, Bing R J, et al. Microbubble dynamics visualized in the intact capillary circulation [ J ]. J Am Coil Cardiol, 1984, 4(3) : 595 -600.
  • 2Hwang M, Lyshchik A, Fleischer A C. Molecular sonography with targeted microbubbles: current investigations and potential applications [J]. Ultrasound Q, 2010, 26(2) : 75 -82.
  • 3Stride E P, Coussios C C. Cavitation and contrast: the use of bubbles in ultrasound imaging and therapy[ J]. Proc Inst Mech Eng H, 2010, 224(2) : 171 -191.
  • 4Lavisse S, Paci A, Rouffiac V, et al. In vitro echogenicity characterization of poly[ lactide-coglycolide] (plga) microparticles and preliminary in vivo ultrasound enhancement study for ultrasound contrast agent application[J]. Invest Radiol, 2005, 40(8): 536-544.
  • 5Straub J A, Chickering D E, Church C C, et al. Porous PLGA microparticles: AI-700, an intravenously administered ultrasound contrast agent for use in echocardiography [ J ]. J Control Release, 2005, 108 (1): 21 -32.
  • 6Cui W, Bei J, Wang S, et al. Preparation and evaluation of poly( L- lactide-co-glycolide) (PLGA) microbubbles as a contrast agent for myocardial contrast echocardiography[ J]. J Biomed Mater Res B Appl Biomater, 2005, 73(1) : 171 - 178.
  • 7Farook U, Zhang H B, Edirisinghe M J, et al. Preparation of microbubble suspensions by co-axial electrohydrodynamic atomization [ J ]. Med Eng Phys, 2007, 29 (7): 749- 754.
  • 8El-Sherif D M, Wheatley M A. Development of a novel method for synthesis of a polymeric ultrasound contrast agent [ J ]. J Biomed Mater Res A, 2003, 66(2) : 347 -355.
  • 9Wheatley M A, Forsberg F, Oum K, et al. Comparison of in vitro and in vivo acoustic response of a novel 50 : 50 PLGA contrast agent[ J ]. Ultrasonics, 2006, 44(4): 360-367.
  • 10El-Sherif D M, Lathia J D, Le N T, et al. Ultrasound degradation of novel polymer contrast agents[ J]. J Biomed Mater Res A, 2004, 68 (1): 71 -78.

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部